June 15, 2020

The U.S. FDA has approved a new indication for Juvéderm® Voluma™ XC (hyaluronic acid), manufactured by Allergan Aesthetics, for augmentation of the chin region to improve the chin profile in adults over the age of 21. The product is the first and only filler approved by the FDA for this purpose.

In a clinical study, Juvéderm Voluma XC was found to be safe and effective for augmentation of the chin. The majority of participants reported high satisfaction throughout one year of follow up. The product is injected by a healthcare professional trained in its use, with effects lasting for up to two years. It is only available by prescription.

Juvederm Voluma XC first received FDA approval in 2013 for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face.

June 18, 2020

Crysvita Receives New Indication to Treat Rare Bone Disease

Read More
June 17, 2020

Keytruda Granted New Indication to Treat Cancer Based on Biomarkers, Regardless of Tumor Type

Read More
June 16, 2020

Mylotarg Receives Expanded Indication for Leukemia

Read More
June 16, 2020

Cosentyx Receives New Indication for Axial Spondyloarthritis

Read More